An Open Label Phase 2 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Jul 2019
Price : $35 *
At a glance
- Drugs Timrepigine emparvovec (Primary)
- Indications Choroideraemia
- Focus Therapeutic Use
- Acronyms REGENERATE; REGENERATE
- 28 Jun 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Aug 2021.
- 28 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 02 Apr 2019 Planned End Date changed from 31 Dec 2020 to 31 Jul 2021.